<DOC>
	<DOCNO>NCT00320398</DOCNO>
	<brief_summary>This study request PMDA confirm optimal dose THR ( total hip replacement ) .</brief_summary>
	<brief_title>Total Hip Replacement Study Of GSK576428 ( Fondaparinux Sodium )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients undergo either elective primary THR ( total hip replacement ) surgery revision THR . Active , clinically significant bleeding ( exclude drainage ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Fondaparinux</keyword>
	<keyword>MOSLL</keyword>
	<keyword>THR</keyword>
	<keyword>VTE</keyword>
	<keyword>Xa factor</keyword>
	<keyword>pentasaccharide</keyword>
	<keyword>Hip Replacement Arthroplasty</keyword>
</DOC>